Abstract The investigation was to improve the bioavailability of acyclovir by incorporating it into solid lipid nanoparticles (SLNs) and chitosen nano structured lipid carriers (NLCs). The aim of present study is to develop chitosan nanoparticle formulation in order to achieve triggered release of anticancer drug encapsulated in chitosan nanoparticle. Evaluation for the potential of novel chitosan nanoparticle for enhanced cytotoxic effects and minimum side effects. The chitosan nanoparticle was prepared according to the ionic gelation method. Using TPP as cross linker with slight modification. After a complete dissolution of chitosan in acetic acid, gamma oryganol (5%) was added to this solution with magnetic stirring. Then TPP (0.5%) was added in drop wise through a syringe at a uniform rate. In this method glacial acetic acid 1.6 % dissolved in distilled water and further chitosan was used in various concentration % (0.25, 0.5, 1:1, 1:5:1, and 2:1). We have replace ascorbic acid with glacial acetic acid. Ratio of chitosan to TPP was varied from 0.25, 0.5, and 1:1, 1:5:1, and 2:1 % with acetic acid (1.6%) and TPP (0.5%) were used.
Keywords Chitosen, Lipid Carrier, Acyclovir.